Attitudes towards personal genomics among older Swiss adults: An exploratory study by Mählmann, Laura et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Attitudes towards personal genomics among older Swiss adults: An
exploratory study
Mählmann, Laura; Röcke, Christina; Brand, Angela; Hafen, Ernst; Vayena, Effy
DOI: https://doi.org/10.1016/j.atg.2016.01.009
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-135646
Published Version
 
 
Originally published at:
Mählmann, Laura; Röcke, Christina; Brand, Angela; Hafen, Ernst; Vayena, Effy (2016). Attitudes
towards personal genomics among older Swiss adults: An exploratory study. Applied and Translational
Genomics, 8:9-15.
DOI: https://doi.org/10.1016/j.atg.2016.01.009
Attitudes towards personal genomics among older Swiss adults: An
exploratory study
Laura Mählmann a,b, Christina Röcke c, Angela Brand b, Ernst Hafen a, Effy Vayena d,⁎
a Institute of Molecular Systems Biology, ETH Zurich, Auguste-Piccard-Hof 1, 8093 Zürich, Switzerland
b Institute for Public Health Genomics, Faculty of Health, Medicine and Life Sciences, Maastricht University, PO Box 616, 6200 MD Maastricht, The Netherlands
c University Research Priority Program “Dynamics of Healthy Aging”, University of Zurich, Andreasstrasse 15/Box 2, 8050 Zurich, Switzerland
d Health Ethics and Policy Lab, Institute of Epidemiology, Biostatistics and Prevention, University of Zurich, Hirschengraben 84, 8001 Zurich, Switzerland
a b s t r a c ta r t i c l e i n f o
Objectives: To explore attitudes of Swiss older adults towards personal genomics (PG).
Methods: Using an anonymized voluntary paper-and-pencil survey, data were collected from 151 men and
women aged 60–89 years attending the Seniorenuniversität Zurich, Switzerland (Seniors' University). Analyses
were conducted using descriptive and inferential statistics.
Results: One third of the respondents were aware of PG, and more than half indicated interest in undergoing PG
testing. The primary motivation provided was respondents' interest in ﬁnding out about their own disease risk,
followed bywillingness to contribute to scientiﬁc research. Forty-four percent were not interested in undergoing
testing because results might be worrisome, or due to concerns about the validity of the results. Only a minority
of respondents mentioned privacy-related concerns. Further, 66%were interested in undergoing clinic-based PG
motivated by the opportunity to contribute to scientiﬁc research (78%) and 75% of all study participants indicated
strong preferences to donate genomic data to public research institutions.
Conclusion: This study indicates a relatively positive overall attitude towards personal genomic testing among
older Swiss adults, a group not typically represented in surveys about personal genomics. Genomic data of
older adults can be highly relevant to late life health and maintenance of quality of life. In addition they can be
an invaluable source for better understanding of longevity, health and disease. Understanding the attitudes of
this population towards genomic analyses, although important, remains under-examined.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The emergence of increasingly inexpensive genome sequencing
technologies has increased our potential to identify genetic components
of health and disease, thereby contributing to progress towards more
individualized, predictive, preventive and precise medicine (Van El
et al., 2013). To facilitate this development, genome-wide association
and gene–environment interaction studies have become valuable
resources for investigating the genetic basis of disease.
Capitalizing on hopes and expectations regarding personalized medi-
cine, commercial companies began offering large-scale personal genomic
testing and disease-risk proﬁling outside clinical settings in 2007. Such
companies appeared in many countries, operating via online interfaces
and initially using a direct-to-consumer approach (DTC) whereby users
order tests online and receive personal predictive risk assessments for a
variety of diseases directly,without themediation of a health professional
(Vayena and Prainsack, 2013). However, the analytical validity, clinical
utility of such tests including the appropriate involvement of health care
providers have been highly contested, and signiﬁcant debate has
surrounded these companies ever since their ﬁrst emergence (Bloss
et al., 2013; Vayena et al., 2014a; Vayena, 2014). The leading company
in this area remains 23andme, claiming to have one million genotypes
in their database (23andme, 2015). Since November 2013, at the request
of the US FDA, the company can offer only limited health risk information
depending on whether the FDA has been provided with sufﬁcient evi-
dence of the link between a variant and a condition. In the UK, the same
company offers awider range of health risk information as the UK regula-
tors have not stepped into controlling the services.
Expert views differ over whether this type of genomic risk informa-
tion has any value for disease prevention or would only inappropriately
burden individuals and the healthcare system (Bloss et al., 2013 &
McGowan et al., 2014). Systematic evidence of the impact of personal
genomic information on behavior and health outcomes remains limited.
Overall, early ﬁndings indicate increased physician utilization by DTC-
PG customers (Bloss et al., 2014). Healthier lifestyle changes on the
basis of genomic results was only reported by Egglestone et al.,
(2013), while others observed no changes or even decreased self-
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efﬁcacy and control over one's health (Bloss et al., 2013; Boeldt et al.,
2015). Further, differences in anxiety levels or after test distress in DTC-
PG users were reported as non-signiﬁcant and correct interpretation
and understanding of PG ﬁndings varies with demographic characteris-
tics, level of education and numeracy, genetic knowledge and the format
in which the information is presented (Ostergren et al., 2015; Schmidlen
et al., 2015). Most ﬁndings come from early adopters of DTC-PG. We are
still lacking conclusive evidence of how lay people receiving complex
genomic information would react to it, given the limited genomic lit-
eracy in the general public (Carere et al., 2015; Critchley et al., 2015a,
b; Boeldt et al., 2015 Meisel et al., 2015; Ostergren et al., 2015
Schmidlen et al., 2015; Gigerenzer et al., 2007; Gigerenzer and
Muir Gray, 2011; Wasson et al., 2013).
To date a number of studies have sought to improve understanding
of the attitudes of people who have accessed their genomic data, or
those willing to do so (Carere et al., 2015; Roberts and Ostergren,
2013; Vayena et al., 2012; Vayena et al., 2014a). While patterns have
begun to emerge, empirical data remain limited (Vayena et al.,
2014a): ﬁndings indicate that the general public's awareness about
genomics is increasing, even though the number of actual test takers
remains low (Almeling and Gadarian, 2014; Carere et al., 2015;
Critchley et al., 2015a, b; Hall et al., 2012; Schmidlen et al., 2015). The
most commonly reported motives for undergoing personal genomic
testing outside the clinical context are to obtain information about per-
sonal traits; to explore genetic makeup and ancestry; or wanting to
learn about individual genetic risk factors (Cherkas et al., 2010;
Gollust et al., 2012; McGowan et al., 2010; Vayena et al., 2012; Vayena
et al., 2014a). Other reasons include the use of genetic information for
disease prevention (Rahm et al., 2012); planning to adopt healthier life-
styles in cases of higher-than-average risk (Cherkas et al., 2010); expla-
nation for the cause of a current health condition (Meisel et al., 2015)
and taking personal responsibility for future health (McGowan et al.,
2010). An additional reason has been the opportunity to contribute to
research, despite privacy and conﬁdentiality concerns being reported
as obstacles to the donation of data (Brown Trinidad et al., 2010;
Critchley et al., 2015a, b).One study found people accepting trade-offs
between privacy and the utility of research participation for the com-
mon good (McGuire et al., 2009; Oliver et al., 2012). However, condi-
tions for such trade-offs or expectations associated with utility are still
an underexplored area. Since we anticipate an increase in the use of ge-
nomic data within and beyond the clinical setting, it is important to ﬁll
gaps in empirical data on public attitudes concerning these issues.
Following up on previous work we did on PG attitudes in
Switzerland, this study focuses on investigating perspectives of older
Swiss adults. In most western societies the older adult population is
the fastest growing segment; medical advances and the baby boom
between 1955 and 1964 have resulted in a current population in
which 1/6 of people are 65 or older, with a steadily increasing percent-
age aged 80 or older (BFS 2013). Compared to the general population,
older adults aremore vulnerable to physical changes, decreasingmobil-
ity, chronic illness, loss of support systems, and changes in cognitive
ability, particularly in advanced old age. However, they are also charac-
terized by large inter-individual differences in level, rate and direction
of change of these characteristics. In the context of genetic research,
given their long life history of health and disease, they also represent
an extremely rich source of insight into genetic associations with
human longevity, as well as genetic associations leading to individual
ﬁtness (van den Akker et al., 2015; Tan et al., 2006).
In general, older adults are frequently under-recruited or excluded
from biomedical and pharmaceutical research, although most drugs
and treatments under development are more likely to be used in this
age group. The elderly perspective is also missing from the discussion
of personal genomics, since studies have mainly focused on younger
populations with concerns corresponding to earlier phases in life
where health issues are typically a concern of the future, as opposed to
the more current concern of many older adults (Smith and Freund,
2002; Wurm et al., 2009). This project aimed to start ﬁlling the gap in
our knowledge regarding attitudes of older adults towards human
genomics. More speciﬁcally, we wanted to explore whether this age
group is aware of developments within genetic testing, in particular
personal genomics; their interest in undergoing such testing them-
selves; the motivational factors contributing to their willingness or
lack thereof; how they view access modalities to such data; and their
concerns and expectations in relation to participating in genomics
research. To our knowledge this is the ﬁrst study of this kind.
2. Method
We conducted an anonymized voluntary self-completion survey in
two sessions on 19 November 2013 and 6 March 2014, before lectures
of the Seniors' University Program at the University of Zurich with
approximately 500 older adults attending on the ﬁrst date, and 300 on
the second date. After a short presentation of the study purpose, we
showed a multimedia ﬁle including a soundless black and white anima-
tion and text describing the customer journey of internet-based personal
genomic services. Theﬁlewas developed in collaborationwith the IT sup-
port group of the University of Zurich, and its content, design and presen-
tation were reviewed by experts in genetics, psychology, social science,
medicine, law, ethics, and information technology. The samemultimedia
ﬁle was used in a study we conducted with young adults and results of
which have been published (Vayena et al., 2014a). After the presentation
of the movie, the audience was invited to ask questions of clariﬁcation
about the movie and the project. They were also invited to pick up a
paper-pencil questionnaire, including a pre-paid return envelope, which
was designed based on our previous study of similar research questions
in young adults (Vayena et al., 2012, 2014a), and after reviewing similar
questionnaires in other published studies (Vernez et al., 2013; Wilde
et al., 2011; Gollust et al., 2012). Permission to conduct this studywas re-
ceived by the Research Ethics Committee of the Canton of Zurich.
The questionnaire included 31 multiple-choice and 7-point Likert
scale questions and was pretested among peers and ﬁve older adults un-
related to the study. Questionswere designed to capture awareness about
personal genomics services, motivation for testing, and concerns about
genomic results. Moreover, a number of questionswere included that ex-
plored attitudes towards sharing genomic data and research participation
in genomic research studies. Since the majority of respondents were un-
likely to have had experience with personal genomic testing, we also ex-
plored the motives and concerns of hypothetical participation in testing.
Demographic data were collected including gender, age, education,
health concerns, offspring, importance of religion, and internet usage.
Statistical analysis was carried out using SPSS Statistics 20.0. We
conducted Pearson's chi-squared test and, where required, Fisher's
exact test in order to establish associations between attitudes to person-
al genomics and the demographic variables. Due to our small sample,
the 7-point-Likert scale scores were split into groups for comparison
of different measures by pooling answer categories 1–3 and 5–7. The
neutral category, 4, was excluded. Again, analysis was conducted and
analyzed using Pearson's chi-squared or Fisher's exact test. Signiﬁcance
was accepted at a p b 0.05 level. Participants' answers to open-ended
questions were reported in free text ﬁelds for “other reasons” or addi-
tional comments. These were post-coded into categories and analyzed
qualitatively or saved as illustrating quotations.
3. Results
In total, 151 respondents participated in the survey, a response rate
of 19% based on the total number of attendees at the lecture. General
sample characteristics are displayed in Table 1. Genderwas fairly equal-
ly distributed and the mean age reported was 76 years, with a range
between 60 and 89 years. The level of education was above average,
and 92% of our sample reported regular internet use. Participants
expressed moderate concern about their own health, with 4.89 on a
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7-point Likert-scale, and one third reported being affected by a serious
disease either personally or within their family. The importance of reli-
gion in daily life seemed less prominent. One third of participants
reported having heard of personal genomic testing. Pearson's chi-
squared test revealed that the oldest age group (born 1925–1935)
was less likely to be aware of DTC-PG (χ2 (1,n = 84) = 6.025, p =
0.024), and also reported less internet use ( χ2 (1,-n = 84) = 19.704,
p= 0.0.
3.1. Direct-to-consumer personal genomics (DTC-PG): motivation to
undergo testing
Only one respondent had personal experience with DTC personal
genomics; this person had participated in a research project. Of the
remaining respondents, 56% were interested in hypothetically un-
dergoing DTC-PG. The primary motivation for considering testing
was interest in receiving information about one's personal disease
risk, followed by the wish to contribute to scientiﬁc research
(Table 2). The exploration of demographic characteristics and the
willingness to undergo testing revealed that people concerned
about their health were more likely to consider DTC-GT (χ2 (1,n =
122) = 5.348, p = 0.021).
A χ2-test including all demographic characteristics was conducted
and revealed the following results: People without children or
grandchildren are less concerned about passing on predispositions (χ2
(1,n = 84) = 16.154, p = 0.000); People without children or
grandchildren are less likely to want to ﬁnd out about their genetic
ancestry (χ2 (1,n = 84) = 8.201, p = 0.004); People with sickness in
family are more likely to prefer having health professional supervision
(χ2 (1,n=82)= 4.353, p=0.037; Comparing the two extreme groups
in terms of age, the oldest group (1935–1925) was less likely to prefer
medical professional supervision (χ2 (1,n= 50) = 6.637, p= 0.01).
3.2. Reasons for not being interested in DTC-PG
Those respondents who were not interested in undergoing DTC-PG
(44%) would refrain mainly because of concerns that the results might
worry them (45.5%) and concerns about the validity of the results
(42.4%, see also Table 3).
A χ2-test including the demographic variables was conducted and
revealed the following results: Females see costs as an obstacle (χ2
(1,n = 66) = 3.960, p = 0.047); People with sickness in family are
less likely to report “no utility” (χ2 (1,n = 64) = 7.721, p = 0.005)
and would not undergo testing since it is not prescribed by the doctor
(χ2 (1,n = 64) = 5.217, p = 0.032); People in the oldest age group
are less concerned about privacy (χ2 (1,n = 47) = 5.631, p = 0.02)
and religious people refrain since it is not prescribed by the doctor (χ2
(1,n= 53) = 6.280, p= 0.019).
3.3. Attitudes towards online PG vs clinic-based PG for research purposes
In contrast to 56% interested in an online PG test, 66% of the respon-
dents were interested in participating in a clinic-based personal geno-
mic test for research purposes, with those concerned about their
health more likely to be interested (χ2 (1,n = 122) = 4.419, p =
0.036). Overall, the main reason for interest was the opportunity to
contribute to scientiﬁc research (78%) and second, to help increase the
validity of the test (69%). More speciﬁcally, participants who had expe-
rienced disease personally or in their family weremotivated by their in-
terest in the development of new therapies (χ2 (1,n=97)=7.904, p=
0.005), as well as improving the validity of available personal genomic
tests (χ2 (1,n=97)= 5.489, p=0.019). Participants with lower levels
of education were less interested in developing therapies for affected
family members or themselves (χ2 (1,n = 100) = 6.354, p = 0.012),
and also reported lower interest in genetics generally (χ2 (1,n =
100) = 6.135, p= 0.013).
Of those respondents expressing interest in undergoing clinic-based
PG for research purposes, the vast majority reported an interest in
receiving back their results, with 60% wanting unrestricted access to re-
sults and 30%wanting only to be informed about curable diseases. Only
4 respondents chose not to receive any results, because they doubted
the validity of the results. An additional reason for refusal provided in
the open-ended questions was the potential burden associated with
more information about disease risk.
A χ2-test including the demographic variables was conducted and
revealed the following results: people aware about genetic testing
were less concerned about privacy (χ2 (1,n = 47) = 4.362, p =
0.037). The same holds true for people with sickness in family (χ2
(1,n = 47) = p = 0.040). People without children or grandchildren
reported quality concerns (χ2 (1,n= 47) = , p= 0.029).
Table 1
Demographics.
Sample characteristic N %
Sample size 151
Age 76 years SD = 6.052
Gender Male 82 54.3%
Female 69 45.7%
Children/grandchildren Yes 126 83.4%
No 25 16.6%
Disease in family Yes 48 31.8%
No 99 65.6%
Internet Yes 139 92.1%
No 12 7.9%
Education Secondary school 7 4.6%
Vocational education 67 44.4%
High School 28 18.5%
University degree 49 32.5%
Health Concerned 104 68.9%
Not concerned 19 12.6%
Religion Religious 38 25.2%
Not religious 88 58.3%
Table 2
Ranked reasons for considering undergoing DTC-GT.
Response (N = 84) No of
responses
[%]
I would like to know if I am at risk of certain disease 59 70.2
I would like to contribute my genetic data to scientiﬁc research 53 63.1
I would like to know my sensitivity to certain medication 48 57.1
I would like to ﬁnd out about my genetic ancestry 46 54.8
I would like to know the risk that I have passed a disease
predisposition
on to my children 45 53.6
I would like to ﬁnd out about my genetic traits 36 42.9
I was curious about how such a test works 33 39.3
I am interested in genetics in general 30 35.7
If I were able to buy the test at low cost 29 34.5
Just for fun 5 6
Table 3
Ranked reasons for not being interested DTC-PG.
Response (N = 66) No of
responses
[%]
I am concerned that the results will worry me 30 45.5
I do not think the test results are valid 28 42.4
I do not see any utility in such tests/I am not interested in my
genetic proﬁle
28 42.4
I am concerned about the privacy of my data 18 27.3
I am skeptical about genetic testing in general 14 21.2
Cost is an obstacle to undergo testing 11 16.7
The test is not advised by a doctor 11 16.7
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One third of all respondents were not interested in participating in a
clinical study overall worry about possible test results was cited as the
key reason. The second most common reason was skepticism about
genetic testing in general (see Table 4).
Finally, Fig. 1 illustrates reasons for not interested in undergoing
either DTC-PG or clinic-based PG for research purposes, indicating a
common concern about the nature of the results. Low utility and low
validitywere only attributed to privately and self-administeredDTC-PG.
3.4. Donating genomic data to research institutions
Finally, 75% of all respondents indicated strong preferences to
contribute their genomic data to public research institutions such as
universities or university hospitals as opposed to private institutions
(15%). Forty-ﬁve percent would also support contributing data to
private but not-for-proﬁt institutions.
4. Discussion
4.1. Awareness of personal genomic testing
Some researchers have reported declining awareness of personal
genomic testing with increasing age. Additionally, psychological and
consumer behavior studies link increasing agewith decreasing capacity
for processing information from media sources (Ostergren et al., 2015;
Kolor et al., 2012; Langford et al., 2012), whichmight lead to the report-
ed lower awareness of PG in older people. Since some of the personal
genomics services are online, it is also likely that the low internet use,
especially among the oldest study participants of our group, might
diminish awareness of online genomic services. However, a recent
survey of internet use in older Swiss adults indicated that 68% of those
aged 60–69 and 40.6% of those aged 70 years and older reported using
the internet to some degree (Schelling and Seifert, 2010).
In the present study, one third of participants were familiar with the
concept of personal genomics, a proportion that can be classiﬁed as
moderate compared to other studies involving young and middle-
aged adults (Cherkas et al., 2010; Finney Rutten et al., 2012; Hall et al.,
2012; Kolor et al., 2012; Ortiz et al., 2011). This ﬁnding is likely to be
related to the increasing media attention and current public debate
around a revision of the Swiss laws on genetic testing. In addition, one
of the senior citizens' lectures used for recruitment was on innovations
in medicine, which might imply pre-existing interest in the medical
ﬁeld within our sample.
4.2. Reasons for DTC-PG-testing
Only one person in the current study reported personal experience
with genetic testing in the context of a genetic research study. This is
in line with previous ﬁndings of a relatively low participation rate in
personal genomic testing in other age groups (Kolor et al., 2012; Ortiz
et al., 2011). More than half of our respondents expressed interest to
participate in a hypothetical PG-study. Other studies characterized indi-
viduals with prior personal experience of a genetic disease in them-
selves or within their family as particularly open-minded towards
genetic testing (Kettis-Lindblad et al., 2005); our ﬁndings, however, in-
dicate more critical attitude to personal genomics within this group.
Those with a family history of disease were particularly likely to ques-
tion the utility of this type of test, and indicated that theywould not un-
dergo testing without involving a health professional.
Respondents were interested in access to information on personal
disease risk and the opportunity to contribute to scientiﬁc research.
Those respondents who were concerned about their health in general
expressed a stronger interest in undergoing testing. Similarly, in the
case of a clinic-based PG for research purposes, an additional motive
for participation was to help increase the validity of the test. Other
studies have reported analogous ﬁndings (Goldsmith and Jackson,
2012; Vayena, 2014): the moral duty of contributing — for reasons of
reciprocity— to the societal good; altruism; and self-interest in medical
treatment have all been described as common motivations to partici-
pate in genetic research for elderly groups (Frazier et al., 2006; Merz
et al., 2002). Generally, altruism involves an act in which beneﬁts are
attributed to others rather than the actor; in genetic research, the recip-
ient (a research institution), is considered to reciprocate the gift by
contributing towards publicly accessible medical advances; therefore,
a third party, society, eventually receives the beneﬁts of the individual's
altruistic act (Harmon and Chen, 2012). Erikson and Kivnick (1986)
considered this type of altruism ‘generativity’: an increasing concern,
with age, to guide and care for the next generation, coupledwith greater
willingness to provide positive opportunities for the next generation.
Consequently, participation of the elderly may be seen by older adults
themselves as a reciprocal act, whereby the older adult experiences per-
sonal beneﬁts from participation, including increased or maintained life
Table 4
Ranked reasons for not considering a clinic-based PG for research purposes.
Response (N = 50) No of responses [%]
I am concerned that the results will worry me 23 46
I am skeptical about genetic testing 17 34
I am concerned about the privacy of my data 15 30
I question the validity of the test 9 18
Time would be an obstacle to participating 8 16
I am not interested in genetics at all 5 10
Fig. 1. Comparison of reasons for not undergoingDTC-PG or clinic-based PG for research purposes. To enable comparison and adjust for varying total numbers, data have been normalized.
Categories have been grouped and slightly renamed.
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satisfaction, greater conﬁdence and self-esteem, aswell feelingmore so-
cially integrated through having contributed personally to the common
good and/or the next generation (Harmon and Chen, 2012).
4.3. Reasons for not being interested in PG-testing
The primary reason for refraining from PG-testing was the
possible implications of the results, which might cause worry
(Bloss et al., 2010; Gollust et al., 2012; McGuire et al., 2009; Rahm
et al., 2012; Vayena et al., 2014a). This ﬁnding relates to a rather
prominent point in the debate about PG, namely the concern about
whether people are able to understand the nature of genetic data
and interpret predictive results correctly. Studies of investigating
this question in the context of genetic literacy have had contradicto-
ry results. Some found that people lacked sophisticated knowledge
about genetics and genomics while holding misconceptions about
the value and limitations of genetic tests (Boeldt et al., 2015;
Ostergren et al., 2015; Schmidlen et al., 2015; Hahn et al., 2010;
Rose et al., 2005). Other studies found that participants have realistic
expectations and understand the low predictive power of results
(McGowan et al., 2010; McGuire et al., 2009; Meisel et al., 2015;
Ostergren et al., 2015). It is therefore difﬁcult to draw ﬁrm conclu-
sions at this point about individual perceptions of actual test results.
The risk of being surprised and unable to cope with probabilistic re-
sults might still occur in some instances, especially given the often
observed limited ability of both doctors and patients to interpret
probabilistic information about health risks correctly, even when
those risks are unrelated to genetics (Boeldt et al., 2015; Carere
et al., 2015, Dressler et al., 2014; Gigerenzer et al., 2007;
Gigerenzer and Muir Gray, 2011, Kaye and Korf, 2013; Ostergren
et al., 2015; Powell et al., 2012; Schmidlen et al., 2015). Those with
a family history of disease were more likely to question the utility
of this type of test, and indicated that theywould not undergo testing
without involving a health professional. Another interesting ﬁnding
that emerged in the open questions was that some participants did
not wish to be treated for illness after a certain stage; they were con-
cerned, however, that having genetic information might lead to in-
creased external pressure on them to undergo treatment despite
their own wishes. Although the design of our study did not allow
us to explore this further, we consider this an issue worthy of deeper
investigation.
Given the prominence of privacy concerns in all discussions about
genomic testing, privacy considerations were one of our possible rea-
sons for not undergoing PG testing. Such concerns were very low
among our respondents. A number of other studies have reported con-
cerns about privacy, conﬁdentiality of results and fear of discrimination
as a key consideration in deciding whether or not to participate in ge-
netic research (Critchley et al., 2015a, b; Vayena et al., 2014a;
Goldsmith and Jackson, 2012; McGuire et al., 2009; Wilde et al., 2011).
This is signiﬁcantly different from our ﬁndings and should be explored
in more detail. It is unclear whether lack of privacy concerns is due to
a privacy knowledge gap or whether respondents in this study do not
really consider genetic privacy an issue. Among the older participants
in this study, privacy concerns were very rare, and diminished with in-
creasing age. Given limited previous data on older adults' perception of
privacy in the context of data sharing, we can only assume a number of
reasons. First, many older adults might not be concerned about privacy
because they are not affected by certain risks identiﬁed earlier: for ex-
ample, they do not have employment concerns, they already have
established (health) insurance plans, and they have already survived a
substantial part of adult life. Second, in line with arguments relating
to altruistic motives, older persons might consider the risk of dimin-
ished assurance of privacy due to data disclosure to be outweighed
by the high potential beneﬁts of scientiﬁc research (McGuire and
Burke, 2008; Oliver et al., 2012; Vayena, 2014). Finally another rea-
son that may potentially explain reduced privacy concerns, is the
high level of privacy protection afforded to personal data in
Switzerland (Vayena et al., 2014a). None of our respondents men-
tioned concerns about the privacy of their relatives in relation to
their own genomic testing. A possible explanation could be low ge-
nomic literacy and limited understanding of the genetic privacy im-
plications for relatives. The level of genomic literacy of this
population and the perception of privacy risks need further
exploration.
4.3.1. Comparison of DTC-PG and clinic-based PG
We compared participants' interest in undergoing DTC-PG and per-
sonal genomic testing in a clinical context for research purposes. Ac-
cording to Swiss law, for companies that operate from Switzerland, it
is illegal to offer personal genomic services to consumers without phy-
sician prescription and counseling. It is not illegal for Swiss citizens to
access such services online, but the ministry of health has issued advise
against such online services. The genetic testing law is currently under
revision, which includes relaxing some of these prohibitions, however,
at the time of the survey no revision was effected. We were interested
in exploring whether the context in which the genomic testing takes
place is relevant in people's motivation or concerns. The comparison
was most interesting in relation to the reasons for refraining from
testing. As in the DTC-PG the primary reason was concerns that re-
sults may cause worry. Drawing on other ﬁndings from earlier stud-
ies, although in different age groups, we still observe that this
concern persists as reasons of avoiding personal genomics irrespec-
tive of the context of testing. It is important to explore this sentiment
towards genomic information in more depth. Is the underlying con-
cern the result of a deterministic understanding of genomics, or is it a
general attitude towards information with predictive value? Ulti-
mately better understanding the reasons behind such concerns will
also prove relevant for the design of genomic literacy activities.
4.3.2. Not-for proﬁt vs for-proﬁt
The vast majority of study participants indicated strong preference
to donate data to public research institutions as opposed to private
research institutions. Even though we did not further explore the un-
derlying reasons for this preference, our hypothesis is that people
trust not-for proﬁt publicly funded organizations more for prioritizing
the common good. Given the growingnumber of private for-proﬁt com-
panies operating in the space of genomic and personal data, it would be
interesting to further explore such views also against people's broader
notion of ownership and exploitation of genomic data.
4.4. Limitations of the present study
All participants in this studywere recruited via the Seniorenuniversität
Zurich, a continuing education program for seniors. These seniors are
characterized by an above average level of education and high levels
of social participation and engagement in physical, cultural and social
activities. This proﬁle implies that our sample represents a selected
part of the aging population rather than being fully representative of
the general population. The Seniorenuniversität itself claims that their
members are ‘the pioneers of a new culture of aging’, and such a new
culture is likely to involve higher levels of engagement in activities
such as participating in research. Additionally, future generations of
older adults will also include the so-called baby boom generation,
with demographics more similar to the population in this survey.
The low response rate, 19%,may indicate a substantial group of older
adults outside the study with a critical perspective towards genetics,
with only those holding a sufﬁciently strong preexisting interest in
genetics and genomics actually participating.
We approached this sample in two sessions of a lecture series and in-
troduced the topic by showing an informational multimedia ﬁle. We of-
fered the change to pose clarifying questions, but we did not assess the
viewers' comprehension of the video. The ﬁrst time we approached the
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older adults was before a lecture on new developments in cardiology, a
theme closely related to medical issues. This could imply an a priori in-
creased interest in and awareness of new advances in medicine. Anoth-
er limitation of the study is that due to the limited number of actual test
takers in this age group, we investigated a hypothetical scenario by ask-
ing participants to imagine whether they would participate in genomic
testing, and assessing their motivation for or against such participation.
As our participantswere aware of the hypothetical nature of this scenar-
io, it is possible that motivational responses differed from those in a
real-world test taking situation: the survey respondents might not
have been as emotionally invested in the overall topic and in their deci-
sion as participants in a real-life personal genomic test.
Despite the reported limitations, this study provides a ﬁrst descrip-
tive approach to unveiling attitudes andmotives relating to personal ge-
nomics in later adulthood—a source of information largely untapped,
but one that is likely to inform the current debate and approaches to
policy making.
4.5. Outlook and conclusion
How to harness people's willingness to engage with their genomic
data and contribute to research, while making sure they are not
exploited and their individual rights are not being violated, remains a
key challenge. As PG is a relatively new development we are only at
the beginning of the debate about necessary measures, for example, at
the regulatory level; how to engage the broader public in the debate;
and ultimately how to protect individual rights, like privacy and conﬁ-
dentiality, while avoiding undue paternalism. Although these are global
developments, policies tend to be developed and implemented at the
national level and therefore they need to be responsive to different pub-
lic perceptions about genomics, public trust in scientiﬁc andmedical re-
search, the health care systems, as well as different regulatory regimes.
This exploratory study shows that olderWestern European adults of
higher educational level and with familiarity with online technologies
are generally interested in personal genomics. The participants were
motivated by the possibility to participate in research and interest in
one's actual and future health. This population is of particular impor-
tance for genomic studies. Genomic data from this population can con-
tribute to better understanding of longevity, gene–environment
interactions and wellbeing. In addition, as this segment of the popula-
tion is rapidly growing,more thought should be given on how to involve
this group in genomic research. If that were to be the case, it is impera-
tive to understand the attitudes, preferences and concerns of this popu-
lation group in relation to genomic data. Such an understanding is
crucial for developing appropriate policies and practices in relation to
recruitment, informed consent and privacy-setting options relevant to
personal genomics. We hope that our exploratory ﬁndings will help
set a broader research agenda for genomics and senior adults.
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